宜宾三点一线割双眼皮宜宾割双眼皮前的准备,宜宾医院祛斑要多少钱,宜宾鼻子尖长痘痘,宜宾无痕隆胸术,宜宾割双眼皮割的好,宜宾那双眼皮做的好,宜宾市双眼皮手术大概多少钱

WASHINGTON, July 20 (Xinhua) -- The loss of a protein that coats sperm may explain a significant proportion of infertility in men worldwide, according to a study by an international team of researchers led by University of California Davis.A paper describing the work was published Wednesday in the journal Science Translational Medicine. The research could open up new ways to screen and treat couples for infertility.The gene DEFB126 encodes a protein called Beta Defensin 126, which coats the surface of sperm and helps it penetrate cervical mucus in the female. A survey of samples from the U.S., Britain and China showed that as many as a quarter of men worldwide carry two copies of the defective gene.In the new study, researchers found that men with a muted DEFB126 lack Beta Defensin 126, making it much more difficult for sperm to swim through the mucus and eventually join with an egg.Examining 500 newly married Chinese couples, researchers found that the lack of Beta Defensin 126 in men with the DEFB126 mutation lowered fertility (even among men that did not display other deficiencies usually associated with infertility, like inadequate semen volume and low sperm motility). Wives of men with the Beta Defensin 126 variant were significantly less likely to become pregnant than were other couples, and 30 percent less likely to have a birth.This genetic variation in DEFB126 likely accounts for many unexplained cases of infertility, researchers say. They hope next to work with a major infertility program in the U.S. to further explore the role of the mutation.

WASHINGTON, July 5 (Xinhua) -- Intake of high levels of folate, a water-soluble B vitamin that occurs naturally in food, may reduce colorectal cancer risk, according to a new study published Tuesday in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute. "We found that all forms and sources of folate were associated with lower risk of colorectal cancer," said lead author Victoria Stevens, of the American Cancer Society. "The strongest association was with total folate, which suggests that total folate intake is the best measure to define exposure to this nutrient because it encompasses all forms and sources."Total folate includes naturally occurring food folate and folic acid from fortified foods and dietary supplements.The research team investigated the association between folate intake and colorectal cancer among 99,523 participants in the Cancer Prevention Study II Nutrition Cohort; a total of 1,023 participants were diagnosed with colorectal cancer between 1999 and 2007, a period entirely after folate fortification began. Neither higher nor lower risk was observed during the first two years of follow-up (1999 to 2001), while associations were statistically significantly inverse for the subsequent years (2002 to 2007). The findings of this study add to the epidemiologic evidence that high folate intake reduces colorectal cancer incidence.Folates are essential nutrients needed to make components used for functions required for normal cell growth, including DNA synthesis and repair. Because these processes are critical for cell growth and differentiation, the relationship between folate intake and cancer development has been investigated in several cancers, and most extensively in colorectal cancer.

BEIJING, Sept. 14 (Xinhuanet) -- The U.S. Food and Drug Administration (FDA) on Monday announced a recall on a drug infusion pump of Medtronic, the Associated Press reported.The recalled drug pump was called "SynchroMed II", including models of 8637-20 and 8637-40, distributed between 2004 and July 2011.Drug infusion pump was used to deliver the drugs for patients to treat chronic pain, spasms as well as other conditions.The pumps' malfunction could put patients in the risk of either recurrent or withdrawal symptoms, which could be life-threatening, FDA warned.There were 55 reported cases and one death related to the drug withdrawal, among a total 139,653 SynchroMed II pump implants worldwide, FDA notified.The problem was due to a film within the pump's battery that could stop the therapy, FDA said.Medtronic, the U.S. medical technology company based in Minneapolis, is not recommending patients to remove the pumps, but instead, encourage patients to contact their doctor if they hear the device alarm.

BEIJING, July 11 (Xinhuanet) -- Gay and bisexual men account for around one in every three new cases of HIV in China, according to the latest official statistics released by the Ministry of Health.About 5 percent of the group - officially termed men who have sex with men, or MSM - are living with the virus, which is a rate that is 88 times higher than the national HIV prevalence rate of 0.057 percent.The problem is particularly acute in large urban centers, with the prevalence rate in some southwestern cities reaching almost 20 percent.However, the statistics also show that less than half of all gay and bisexual men have access to HIV screening, while about 15 percent of those who are infected are not receiving treatment."Cities are at the heart of China's development and progress and must remain at the forefront of its HIV response," said Michel Sidibe, executive director of the Joint United Nations Programme on HIV/AIDS (UNAIDS), during a workshop about the HIV impact on MSM on Saturday in Chengdu, capital of Southwest China's Sichuan province."Through bold action cities can lead the way to achieving the UNAIDS vision of zero new HIV infections, zero discrimination and zero AIDS-related deaths," he said, according to a UNAIDS news release. "We hope that over the next year, many more Chinese cities will implement MSM strategies."Almost 10 percent of gay and bisexual men in Chengdu are HIV-positive, according to Yang Xiaoguang, director of the city's health bureau. He agreed with Sidibe that cities have a crucial role to play in AIDS prevention and added: "By working to build a strong, multi-sector response in Chengdu, with meaningful community participation, we can scale-up coverage of prevention, treatment and care services among MSM and halt the spread of HIV."During the workshop, senior Chinese health officials, representatives from civil societies and other delegates discussed a new five-year strategy that increases coverage of HIV prevention and treatment for the MSM population and promotes the participation of community organizations.Government estimates put China's population of gay men at between 5 and 10 million, although Zhang Beichuan, a leading expert on HIV at Qingdao University, puts the number closer to 30 million.Tong Ge, coordinator of China's MSM Health Forum, noted the importance of ensuring strong cooperation between the government and society."By building on the experiences of cities like Chengdu, which already have well developed AIDS responses, we can help promote multi-sector collaboration on an equal, orderly basis and strengthen the response to HIV nationwide," he said. "The next step will be to implement similar strategies in other cities nationwide."Chengdu's new strategy underscores the critical role community organizations can play in reaching MSM and other populations at a higher risk of infection, experts at the workshop said.In 2009, China had an estimated 740,000 people living with HIV/AIDS, according to UNAIDS statistics.

LOS ANGELES, June 5 (Xinhua) -- U.S. researchers have developed two new drugs that can prolong the lives of patients with advanced melanoma, it was announced on Sunday.Research on both drugs was presented at the on-going annual meeting of the American Society of Clinical Oncology in Chicago, according to HealthDay News.This is the first big news in years for treatment of melanoma, one of the deadliest forms of skin cancer and one that is notoriously difficult to treat, let alone cure, the report said.The first treatment, vemurafenib, inhibits a gene mutation harbored in half of all melanoma patients, but is not yet approved by the U.S. Food and Drug Administration.The other drug, Yervoy (ipilumumab), is an immune system therapy that won approval in March."The March FDA approval of ipilumumab (Yervoy) was the first new drug approval for melanoma in 13 years," said Tim Turnham, executive director of the Melanoma Research Foundation.The two drugs were developed by researchers at Memorial Sloan- Kettering Cancer Center in New York City, the report said."This is really a huge step toward personalized care in melanoma," Dr. Paul Chapman, lead author of the first study and the attending physician in the melanoma/sarcoma service at Memorial Sloan-Kettering, said in a statement. "This (vemurafenib) is the first successful melanoma treatment tailored to patients who carry a specific gene mutation in their tumor, and could eventually become one of only two drugs available that improves overall survival in advanced cancers.""Having two trials that show a benefit in survival in patients with melanoma, both of these in first-line settings -- we weren't here just a few years ago," said Dr. Stephen Hodi, director of the Melanoma Center at Dana Farber Cancer Institute in Boston. "These are huge, paradigm-shifting results for the field."In the vemurafenib trial, sponsored by the drug's makers, researchers randomly assigned 675 patients with advanced, inoperable melanoma to receive either the chemotherapy drug dacarbazine or vemurafenib. Vemurafenib targets the V600E mutation in the BRAF gene.At the three-month mark, patients taking vemurafenib were 63 percent less likely to die and 74 percent less likely to die or see their cancer return, compared to patients taking dacarbazine alone.Few patients had side effects in the vemurafenib group, although some did develop squamous cell carcinoma, a less dangerous form of skin cancer.This is the first drug that has been proven superior to chemotherapy in this group of hard-to-treat patients, the researchers said."There was such a substantial benefit that we recommended that patients cross over," Chapman said at a Sunday news briefing. "It' s unprecedented to report a trial this early. The median follow-up time was three months." Yet the differences between the two groups became evident almost immediately.Dr. Lynn Schuchter, co-moderator of the briefing and division chief of hematology-oncology at Abramson Cancer Center of the University of Pennsylvania in Philadelphia, said symptoms subsided in some patients almost immediately, enabling them to cut back on pain medication in just 72 hours."The median time to progression with dacarbazine was 1.6 months versus three months with vemurafenib, which is a huge difference," said Chapman.In the second study, about 500 patients were randomly picked to receive Yervoy plus dacarbazine or dacarbazine alone.Those taking both drugs lived a median of 11.2 months compared to 9.1 months for those taking dacarbazine alone. Time to recurrence of disease was about the same for both groups: 2.8 months and 2.6 months, respectively.Almost half of those taking the combination therapy were alive after one year, compared to 36.3 percent in the other group. After two years, the rates were 28.5 percent and 17.9 percent, respectively.By three years out, 20.8 percent of those in the combination group were alive compared with 12.2 percent of those taking chemotherapy alone.This is the first study to combine chemotherapy and immunotherapy both safely and effectively.A study to test vemurafenib in combination with Yervoy has already begun, according to HealthDay News.